A bis-boron boramino acid PET tracer for brain tumor diagnosis
European Journal of Nuclear Medicine - Trang 1-10 - 2024
Tóm tắt
Boramino acids are a class of amino acid biomimics that replace the carboxylate group with trifluoroborate and can achieve the 18F-labeled positron emission tomography (PET) and boron neutron capture therapy (BNCT) with identical chemical structure. This study reports a trifluoroborate-derived boronophenylalanine (BBPA), a derived boronophenylalanine (BPA) for BNCT, as a promising PET tracer for tumor imaging. Competition inhibition assays in cancer cells suggested the cell accumulation of [18F]BBPA is through large neutral amino acid transporter type-1 (LAT-1). Of note, [18F]BBPA is a pan-cancer probe that shows notable tumor uptake in B16-F10 tumor-bearing mice. In the patients with gliomas and metastatic brain tumors, [18F]BBPA-PET shows good tumor uptake and notable tumor-to-normal brain ratio (T/N ratio, 18.7 ± 5.5, n = 11), higher than common amino acid PET tracers. The [18F]BBPA-PET quantitative parameters exhibited no difference in diverse contrast-enhanced status (P = 0.115–0.687) suggesting the [18F]BBPA uptake was independent from MRI contrast-enhancement. This study outlines a clinical trial with [18F]BBPA to achieve higher tumor-specific accumulation for PET, provides a potential technique for brain tumor diagnosis, and might facilitate the BNCT of brain tumors.
Tài liệu tham khảo
Liu Z, Chen H, Chen K, Shao Y, Kiesewetter DO, Niu G, et al. Boramino acid as a marker for amino acid transporters. Sci Adv. 2015;1:e1500694.
Li Z, Kaiser L, Holzgreve A, Ruf VC, Suchorska B, Wenter V, et al. Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F]FET PET radiomics. Eur J Nucl Med Mol Imag. 2021;48:4415–25.
Heinzel A, Stock S, Langen K-J, Müller D. Cost-effectiveness analysis of FET PET-guided target selection for the diagnosis of gliomas. Eur J Nucl Med Mol Imag. 2012;39:1089–96.
Harat M, Rakowska J, Harat M, Szylberg T, Furtak J, Miechowicz I, et al. Combining amino acid PET and MRI imaging increases accuracy to define malignant areas in adult glioma. Nat Commun. 2023;14:4572.
Langen K-J, Watts C. Amino acid PET for brain tumours — ready for the clinic? Nat Rev Neurol. 2016;12:375–6.
Li J, Shi Y, Zhang Z, Liu H, Lang L, Liu T, et al. A metabolically stable Boron-Derived Tyrosine serves as a Theranostic Agent for Positron Emission Tomography guided Boron Neutron capture Therapy. Bioconjug Chem. 2019;30:2870–8.
Lan X, Fan K, Cai W. First-in-human study of an (18)F-labeled boramino acid: a new class of PET tracers. Eur J Nucl Med Mol Imaging. 2021;48:3037–40.
Li Z, Kong Z, Chen J, Li J, Li N, Yang Z, et al. 18F-Boramino acid PET/CT in healthy volunteers and glioma patients. Eur J Nucl Med Mol Imaging. 2021;48:3113–21.
Kong Z, Li Z, Chen J, Ma W, Wang Y, Yang Z, et al. Larger 18F-fluoroboronotyrosine (FBY) active volume beyond MRI contrast enhancement in diffuse gliomas than in circumscribed brain tumors. EJNMMI Res. 2022;12:22.
Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18:170–86.
Wen PY, Reardon DA. Progress in glioma diagnosis, classification and treatment. Nat Rev Neurol. 2016;12:69–70.
Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, et al. Glioma Nat Rev Dis Primers. 2015;1:15017.
Havu-Aurén K, Kiiski J, Lehtiö K, Eskola O, Kulvik M, Vuorinen V, et al. Uptake of 4-borono-2-[18 F] fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET. Eur J Nucl Med Mol Imag. 2007;34:87–94.
Nariai T, Ishiwata K, Kimura Y, Inaji M, Momose T, Yamamoto T, et al. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma. Appl Radiat Isot. 2009;67:348–S50.
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23:1231–51.
Kong Z, Li Z, Chen J, Liu S, Liu D, Li J et al. Metabolic characteristics of [18F]fluoroboronotyrosine (FBY) PET in malignant brain tumors. Nucl Med Biol. 2022;106–7:80–7.
Kong Z, Zhang Y, Liu D, Liu P, Shi Y, Wang Y, et al. Role of traditional CHO PET parameters in distinguishing IDH, TERT and MGMT alterations in primary diffuse gliomas. Ann Nucl Med. 2021;35:493–503.
Chen J, Li C, Hong H, Liu H, Wang C, Xu M, et al. Side chain optimization remarkably enhances the in vivo stability of 18F-labeled glutamine for tumor imaging. Mol Pharm. 2019;16:5035–41.
Wollring MM, Werner J-M, Ceccon G, Lohmann P, Filss CP, Fink GR, et al. Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas. J Neurooncol. 2023;162:481–8.
Rozenblum L, Zaragori T, Tran S, Morales-Martinez A, Taillandier L, Blonski M, et al. Differentiating high-grade glioma progression from treatment-related changes with dynamic [18F]FDOPA PET: a multicentric study. Eur Radiol. 2023;33:2548–60.
Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018;392:432–46.
Bi JF, Chowdhry S, Wu SH, Zhang WJ, Masui K, Mischel PS. Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets. Nat Rev Cancer. 2020;20:57–70.
Kim MM, Parolia A, Dunphy MP, Venneti S. Non-invasive metabolic imaging of brain tumours in the era of precision medicine. Nat Rev Clin Oncol. 2016;13:725–39.
Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010;9:906–20.
Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med. 1998;39:778–85.
Deuschl C, Kirchner J, Poeppel TD, Schaarschmidt B, Kebir S, El Hindy N, et al. (11)C-MET PET/MRI for detection of recurrent glioma. Eur J Nucl Med Mol Imaging. 2018;45:593–601.
Nodwell MB, Yang H, Čolović M, Yuan Z, Merkens H, Martin RE, et al. 18F-Fluorination of Unactivated C–H bonds in branched aliphatic amino acids: direct synthesis of Oncological Positron Emission Tomography Imaging agents. J Am Chem Soc. 2017;139:3595–8.
Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, et al. [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro Oncol. 2013;15:341–51.
Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, et al. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11 C]methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys. 2011;81:1049–58.
Galldiks N, Niyazi M, Grosu AL, Kocher M, Langen KJ, Law I, et al. Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. Neuro Oncol. 2021;23:881–93.
Hanaoka K, Watabe T, Naka S, Kanai Y, Ikeda H, Horitsugi G, et al. FBPA PET in boron neutron capture therapy for cancer: prediction of 10B concentration in the tumor and normal tissue in a rat xenograft model. EJNMMI Res. 2014;4:70.
Miyatake S, Kawabata S, Yokoyama K, Kuroiwa T, Michiue H, Sakurai Y, et al. Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas. J Neurooncol. 2009;91:199–206.
Linz U. Boron neutron capture therapy for glioblastoma: is it worth pursuing? Technol Cancer Res Treat. 2008;7:83–8.